Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

67Cu-SARTATE Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

Next Previous
X
Search
Trial Profile

67Cu-SARTATE Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary) ; 67Cu-MeCOSar-Octreotate-Clarity-Pharmaceuticals (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Clarity Pharmaceuticals

    • Most Recent Events

    • 28 Aug 2023 According to a NorthStar Medical Radioisotopes media release, first participant of cohort 4 has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar's electron accelerator-produced Cu-67.
    • 23 Aug 2022 Results published in the Media Release
    • 23 Aug 2022 According to a Clarity Pharmaceuticals media release, additional therapy cycles of 67Cu SARTATE have been requested by clinical sites and administered to participants in cohort 1, cohort 2 and additional clinical sites will be opening in the US in the coming months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top